Reuters: Regulatory News: House Republicans to FDA: no meningitis action without documents

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

House Republicans to FDA: no meningitis action without documents Nov 19th 2012, 20:44 Mon Nov 19, 2012 3:44pm EST * Republicans give FDA until Nov. 30 to produce documents * Democrats who joined earlier request not part of new call By David Morgan WASHINGTON, Nov 19 (Reuters) - Republicans on a congressional panel investigating a deadly meningitis outbreak linked to tainted drugs have told the top U.S. drug regulator not to expect new authority to prevent future problems until the agency hands over documents about its role in the current crisis. As the number of meningitis cases edged toward the 500-mark, the House of Representatives Energy and Commerce Committee's Republican majority staff released on Monday a letter that gave the Food and Drug Administration until the end of November to comply with a document request first made in mid-October. "We need these documents to identify any possible weaknesses in FDA's regulatory system that can be immediately corrected administratively or legislatively," said the letter, dated Nov. 16 and addressed to FDA Commissioner Margaret Hamburg by four Republicans, including committee chairman Fred Upton. "This committee has a long history of thoroughly and deliberatively investigating problems and offering solutions. We cannot and will not be in a position to do so in this case until we have a full accounting," the letter said. FDA officials had no immediate comment. The regulatory agency has asked lawmakers to clarify its authority to oversee large-scale drug compounders like Massachusetts-based New England Compounding Center, the maker of epidural steroid injections that have been linked to a fungal meningitis outbreak that has now killed 33 people in 19 states. Drug compounding is a longstanding practice in which pharmacists alter or recombine existing drugs to meet the special needs of specific patients. Some compounders have evolved into large-scale producers that experts say should be subject to FDA regulation. State pharmacy boards are primarily responsible for oversight at the moment. FDA officials say their authority to oversee compounders has been challenged regularly in federal court, leading to conflicting rulings in different parts of the country. A handful of House Democrats have called for congressional action to bring clarity to the situation before year end. But at a committee hearing on Nov. 14, several Republicans charged that FDA already had the authority to avoid the outbreak but failed to, despite repeated problems at NECC. On Oct. 17 the committee submitted a bipartisan request for FDA documents relating to the outbreak including its dealings with NECC and the Massachusetts pharmacy board that was the primary regulator for NECC. The latest letter to FDA contained no Democratic signatures. House committee Democrats were not immediately available for comment. Republicans said a similar request to Massachusetts health authorities produced thousands of internal state emails. "FDA has provided the committee with zero. In fact, when asked by committee staff on Nov. 16, FDA staff stated that they had not even begun to search for responsive emails," their letter said. The House approach to the issue of new regulation stands in contrast with the Democrat-controlled Senate, where lawmakers on both sides of the aisle have expressed a willingness to move ahead with measures that could fundamentally change the regulatory landscape for compounders. The current outbreak is only the biggest and most recent health problem linked to tainted compounded drugs, and Hamburg has warned lawmakers that more outbreaks will occur if regulations do not change. The compounding pharmacy industry has waged successive legislative and legal battles over the years to stave off stricter federal regulations. Link this Share this Digg this Email Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions